fbpx

Multiple Sclerosis Study

Multiple Sclerosis is an unpredictable disease that deteriorates the protective covering of the nerves, which causes poor nerve-to-nerve communication throughout the body. More than 2.3 million people worldwide have a diagnosis of MS. There are two main types of MS; Relapsing, where there are short distinct periods of worsening symptoms that may resolve, and Progressive, where symptoms get worse over time. There are a wide variety of symptoms that include vision loss, fatigue, impaired coordination, numbness, and pain. This disease unfortunately does not have a cure, but there are new treatments in the pipeline seeking to improve the lives of patient who suffer from this disease. 

  • We currently have a study for patients suffering from Relapsing Multiple Sclerosis. This trial is looking at how the study medication compares to an already FDA approved medication. Patients who qualify to participate in this study will be placed on a regimen of either the study medication or Aubagio® (teriflunomide) to treat their MS for up to two years. If you like the treatment, there is also an open label extension phase where you can receive the study medication for up to another 2.5 years. Click the button to view information about this study on clinicaltrials.gov.  Learn More

At NEICR all of our clinical trials (and procedures associated with them) come at no cost to you. There may be compensation to you for your time and travel. If you are interested in participating or have any questions, feel free to fill out the form below or give us a call at (203) 914-1903 for more information.

 

Use the form below to let us know you are interested:

Multiple Sclerosis - Clinical Study Enrollment
First
Last
Sending